EQIPD logo


Start Date
End Date
IMI2 - Call 9
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
4 495 523
EFPIA in kind
4 609 347
255 822
Total Cost
9 360 692


Poor quality data is an issue in many research fields – all too often, results carried out in one organisation cannot be replicated elsewhere, and it is not always clear why. In medical research, consequences include poor decision-making resulting in higher failure rates and longer drug development times. There is therefore an urgent need for simple, sustainable solutions to improve data quality, and that’s where the EQIPD project comes in. Their goal is to deliver simple recommendations to facilitate data quality without impacting innovation.

The project team will start by analysing the variables in study design and data analysis that influence outcomes and establishing whether these are the same in academia and industry. They will then define the components of an EQIPD quality management system and work to achieve a consensus among different stakeholders on quality management recommendations for research. They will also assess the feasibility of the quality management system in prospective studies in the fields of neuroscience and safety.

Finally, the project will set up an online educational platform that will deliver certified courses in the principles and application of data quality and rigour. This, combined with the involvement in the project of many junior scientists, will pave the way for a cultural change in approaches to data quality in the medical research and drug development field.

Achievements & News

Quality matters: making sure research data is fit for its intended use
November 2021

The EQIPD project has developed a wiki-based quality system to help increase adherence to rigorous, evidence-based practices in preclinical research. ### In an interview with the IMI Programme Office, the project’s Malcolm McLeod explains the replicability problem the project sought to address.

‘Often, laboratories find it difficult to replicate research findings from the published literature. When studied, this is true for at least a third of research findings subjected to a replication studies, across a wide range of research fields,’ he says. ‘This might occur because the first finding was wrong, or because of (perhaps very subtle) differences in how the research was done.’

EQIPD has come up with a range of resources to help researchers ensure their work can be replicated. A highlight here is the EQIPD Quality System, which Professor McLeod believes could be particularly useful for academic research groups. ‘The self-assessment tool, in particular, provides a means for such labs to identify their strengths and weaknesses; and by sharing that self-assessment with funders, to demonstrate their approach to research quality,’ he says.

Find out more

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Institut De Recherches Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Orion Oyj, Espoo, Finland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Psychogenics Inc, Tarrytown, United States
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Teva Pharmaceutical Industries Limited, Netanya, Israel
  • UCB Biopharma, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Rijksuniversiteit Groningen, Groningen, Netherlands
  • Stichting Buro Ecnp, Utrecht, Netherlands
  • Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
  • The University Of Edinburgh, Edinburgh, United Kingdom
  • Universitaet Bern, Bern, Switzerland
  • Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany
  • University Of Aberdeen, Aberdeen, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Concentris Research Management GMBH, Fürstenfeldbruck, Germany
  • Noldus Information Technology BV, Wageningen, Netherlands
  • Paasp GMBH, Heidelberg, Germany
  • Pharmalex Belgium, Mont Saing Guibert, Belgium
  • Porsolt SAS, Le Genest-Saint-Isle, France
  • Science Exchange, Inc., Palo Alto, United States
  • Synaptologics BV, Amsterdam, Netherlands
Project leader
Thomas Steckler